stepholidine

01/01/2023 - "QAP14 40 mg/kg showed the best inhibitory efficacy, for it provided the longest prolongation of metastasis-free periods compared with fenoldopam or l-stepholidine. "
01/01/2023 - "Our model structure also fitted well to other D1DR agonists (fenoldopam and l-stepholidine) which had inhibitory impact on breast cancer lung metastasis likewise. "
09/15/2019 - "The two dopamine D1 receptor agonists, fenoldopam (FEN) and l-stepholidine (l-SPD), performed well in decreasing lung metastasis in 4T1 breast cancer model. "

03/01/1992 - "The protective effects of tetrahydroprotoberberines (THPB), viz., l-tetrahydropalmatine (THP), l-stepholidine (SPD), and tetrahydroberberine (THB) on experimental myocardial infarction by ligating the left coronary artery were estimated in rats. "

05/01/1991 - "l-Stepholidine (SPD) has been shown to be effective in treating migraine, but its mechanism is not clear. "

10/01/1988 - "[A controlled study on the treatment of tardive dyskinesia using 1-stepholidine]."
01/01/2003 - "To determine whether the following interventions were associated with a reduction of neuroleptic induced tardive dyskinesia: botulin toxin, endorphin, essential fatty acid, EX11582A, ganglioside, insulin, lithium, naloxone, oestrogen, periactin, phenylalanine, piracetam, stepholidine, tryptophan, neurosurgery, or ECT. "

09/01/2006 - "Effects of (-)stepholidine in animal models for schizophrenia."
12/04/2009 - "Enantioselective total synthesis of (-)-(S)-stepholidine, a drug candidate for the treatment of schizophrenia and/or drug abuse, is described. "
11/01/2009 - "L-stepholidine, an active ingredient of the Chinese herb Stephonia, is the first compound known to have mixed dopamine D(1) receptor agonist/D(2) antagonist properties and to be a potential treatment medication for schizophrenia. "
08/01/2008 - "Thus, l-stepholidine shows efficacy like an "atypical" antipsychotic in traditional animal models predictive of antipsychotic activity and shows in vitro and in vivo D(1) agonism, and, if its rapid elimination does not limit its actions, it could provide a unique therapeutic approach to schizophrenia."
01/01/2007 - "This unique pharmacological profile made dihydroxyl-THPBs such as l-stepholidine (l-SPD) potential agents in the treatment of drug addiction, Parkinson's disease, and especially, schizophrenia. "